GlassScriptPhysician profile
Shirley Chang
NPI 1720063753
$1,933.31
in general payments reported to CMS, 2019-2025
10 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.07 · 2020: $99.99 · 2021: $84.99 · 2022: $200 · 2023: $128 · 2024: $280 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424 · Education: $24.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.46 |
| Education | $24.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $420.16 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $299.98 | 2020-2022 | |
| Travere Therapeutics, INC. | $291.87 | 2024-2025 | Filspari |
| Apellis Pharmaceuticals, INC. | $219.62 | 2025 | |
| Mallinckrodt Hospital Products INC. | $139.48 | 2025 | Terlivaz |
| Novo Nordisk Health Care Ag | $127.94 | 2023 | |
| Alexion Pharmaceuticals, INC. | $125.21 | 2025 | Ultomiris |
| Glaxosmithkline, LLC. | $124.99 | 2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $99.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $84.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shirley Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.